Chapter Title: Management of Acute Coronary Syndrome

Introduction to Acute Coronary Syndrome Management

The American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend that a 12-lead ECG should be performed within the first 10 minutes of arrival in patients with symptoms suggestive of acute coronary syndrome 1
The ECG is a crucial diagnostic tool that determines the management strategy in patients with suspected acute myocardial infarction, with changes in the ST-T segment and Q waves allowing clinicians to date the event, suggest the related artery, and estimate the amount of myocardium at risk 1, 2, 3

The presence of ST-segment elevation or new ischemic changes in contiguous leads indicates the need for urgent revascularization via catheterization 1, 2
Serial ECGs at 15-30 minute intervals during the first hour are indicated in symptomatic patients with a non-diagnostic initial ECG 1
Troponin levels should be measured at presentation and 3-6 hours after the onset of symptoms in all patients with symptoms consistent with acute coronary syndrome, with an elevation of troponin >99th percentile establishing the diagnosis of myocardial infarction 1, 3, 4

The decision to perform urgent catheterization is based on electrocardiographic findings, not troponin levels 1
The AHA/ACC guidelines recommend that patients with acute coronary syndrome should receive aspirin and clopidogrel as part of their initial management, with a loading dose of clopidogrel followed by a maintenance dose 1
The use of beta-blockers, ACE inhibitors, and statins is also recommended in the management of acute coronary syndrome, with the goal of reducing morbidity and mortality 1, 3

The American College of Cardiology recommends that patients with established coronary artery disease should receive the influenza vaccine as part of their preventive care, with the goal of reducing the risk of future cardiovascular events 1
The use of statins should be optimized to achieve a target LDL level of <70 mg/dL in patients with very high-risk cardiovascular disease, such as those with a history of myocardial infarction and diabetes 1

The AHA/ACC guidelines recommend that patients who have received a drug-eluting stent for acute coronary syndrome should receive dual antiplatelet therapy (aspirin and clopidogrel) for at least 12 months, with the goal of reducing the risk of stent thrombosis 1, 3
The decision to extend dual antiplatelet therapy beyond 12 months should be individualized, based on the patient's risk of ischemic events versus bleeding complications 1, 3